Literature DB >> 22871094

The changes of blood platelet activation in breast cancer patients before surgery, after surgery, and in various phases of the chemotherapy.

Magdalena Kedzierska1, Urszula Czernek, Katarzyna Szydłowska-Pazera, Piotr Potemski, Janusz Piekarski, Arkadiusz Jeziorski, Beata Olas.   

Abstract

Blood platelets from patients with cancer (before or after the surgery) exhibit a variety of qualitative abnormalities. Different anti-cancer drugs may also induce the oxidative/nitrative stress in blood platelets and change their hemostatic properties. The aim of our study was to explain the effect of superoxide anion radicals ([Formula: see text]) production on hemostatic properties of blood platelets (activated by a strong physiological agonist - thrombin) from breast cancer patients before the surgery, after the surgery, and after various phases (I-IV) of chemotherapy (doxorubicin and cyclophosphamide). Patients were hospitalized in the Department of Oncological Surgery and at the Department of Chemotherapy, Medical University of Lodz, Poland. We measured the platelet aggregation as the marker of hemostatic activity of blood platelets. We observed an increase of [Formula: see text] in thrombin-activated blood platelets from patients with breast cancer (before or after the surgery and after various phases of the chemotherapy) compared to the healthy group. Our other experiments demonstrated that aggregation (induced by thrombin) of blood platelets from patients with breast cancer before the surgery, after the surgery, and after various phases of the chemotherapy differs from aggregation of platelets obtained from healthy volunteers. Moreover, our results showed the correlation between the [Formula: see text] generation and changes of platelet aggregation in breast cancer patients before the surgery, after the surgery, and after the chemotherapy (I and IV phases). Considering the data presented in this study, we suggest that the production of [Formula: see text] in blood platelets (activated by thrombin) obtained from breast cancer patients may induce the changes of platelet aggregation, which may contribute in thrombosis in these patients.

Entities:  

Mesh:

Year:  2012        PMID: 22871094     DOI: 10.3109/09537104.2012.711866

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  7 in total

1.  Hydroxyethyl starch 200/0.5 decreases circulating tumor cells of colorectal cancer patients and reduces metastatic potential of colon cancer cell line through inhibiting platelets activation.

Authors:  Hua Liang; Chengxiang Yang; Bin Zhang; Hanbing Wang; Hongzhen Liu; Zhenlong Zhao; Zhiming Zhang; Xianjie Wen; Xiaohong Lai
Journal:  Med Oncol       Date:  2015-04-02       Impact factor: 3.064

2.  Evaluation of antitumor activity of platelet microbicidal protein on the model of transplanted breast cancer in CBRB-Rb(8.17)1Iem mice.

Authors:  Iuri B Ivanov; Viktor A Gritsenko; Sergey A Miroshnikov
Journal:  Pathol Oncol Res       Date:  2014-11-30       Impact factor: 3.201

3.  Prognostic and clinicopathological significance of platelet to lymphocyte ratio in esophageal cancer: a meta-analysis.

Authors:  Juhong Deng; Peng Zhang; Yue Sun; Ping Peng; Yu Huang
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

4.  A Three-Dimensional Microfluidic Device for Monitoring Cancer and Chemotherapy-Associated Platelet Activation.

Authors:  Zhujing Hao; Haichen Lv; Ruopeng Tan; Xiaolei Yang; Yang Liu; Yun-Long Xia
Journal:  ACS Omega       Date:  2021-01-22

5.  Development and Validation of a Novel Nomogram for Predicting Tumor-Distant-Metastasis in Patients with Early T1-2 Stage Lung Adenocarcinoma.

Authors:  WeiGuo Gu; MingBin Hu; WeiJia Wang; Chao Shi; JinHong Mei
Journal:  Ther Clin Risk Manag       Date:  2020-12-10       Impact factor: 2.423

6.  The Potential Role of Senescence As a Modulator of Platelets and Tumorigenesis.

Authors:  Claudio A Valenzuela; Ricardo Quintanilla; Rodrigo Moore-Carrasco; Nelson E Brown
Journal:  Front Oncol       Date:  2017-08-28       Impact factor: 6.244

7.  Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients.

Authors:  Shuang Fu; Zhi-Yuan Yun; Ming-Ming Cui; Hongxue Meng; Cheng Qian; Tiemin Liu; Zhi-Ping Liu; Rui-Tao Wang; Kai-Jiang Yu
Journal:  Oncotarget       Date:  2017-06-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.